2 weeks Ago By ABMN Staff
Canada Pension Plan Investment Board purchased a new position in BioLife Solutions, Inc. ( NASDAQ:BLFS – Free Report ) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 5,700 shares of the medical equipment provider’s stock, valued at approximately $122,000.
Other large investors have also recently made changes to their positions in the company. 1620 Investment Advisors Inc. bought a new stake in BioLife Solutions during the second quarter valued at $35,000.
Isthmus Partners LLC raised its position in BioLife Solutions by 34.4% during the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 42,265 shares in the last quarter.
Register Financial Advisors LLC purchased a new stake in BioLife Solutions during the first quarter valued at about $96,000. Arizona State Retirement System purchased a new stake in BioLife Solutions during the second quarter valued at about $217,000. Finally, State Board of Administration of Florida Retirement System purchased a new stake in BioLife Solutions during the first quarter valued at about $229,000.
93.24% of the stock is owned by institutional investors. BioLife Solutions Stock Up 0.
7 % BLFS opened at $24.34 on Friday. The company has a market cap of $1.
12 billion, a P/E ratio of -17.14 and a beta of 1.87.
The business’s 50-day moving average price is $24.44 and its 200-day moving average price is $21.20.
The company has a current ratio of 2.86, a quick ratio of 1.81 and a debt-to-equity ratio of 0.
04. BioLife Solutions, Inc. has a 12 month low of $8.
92 and a 12 month high of $26.73. Analyst Ratings Changes BLFS has been the topic of a number of research reports.
Craig Hallum raised their price target on BioLife Solutions from $23.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, August 12th.
TD Cowen raised their price target on BioLife Solutions from $20.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, July 17th.
Finally, Northland Securities lifted their price objective on BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday, August 9th.
One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. According to data from MarketBeat.com, BioLife Solutions currently has an average rating of “Moderate Buy” and an average price target of $26.
20. Get Our Latest Analysis on BLFS Insider Activity at BioLife Solutions In related news, insider Sarah Aebersold sold 3,000 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $21.
03, for a total transaction of $63,090.00. Following the transaction, the insider now owns 61,683 shares in the company, valued at approximately $1,297,193.
49. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website . In related news, insider Sarah Aebersold sold 3,000 shares of the business’s stock in a transaction dated Monday, July 1st.
The stock was sold at an average price of $21.03, for a total transaction of $63,090.00.
Following the transaction, the insider now owns 61,683 shares in the company, valued at approximately $1,297,193.49. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website .
Also, EVP Aby J. Mathew sold 10,000 shares of the business’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $23.
90, for a total value of $239,000.00. Following the transaction, the executive vice president now owns 317,716 shares in the company, valued at approximately $7,593,412.
40. The disclosure for this sale can be found here . Insiders have sold a total of 19,944 shares of company stock worth $468,709 in the last 90 days.
Company insiders own 2.20% of the company’s stock. BioLife Solutions Company Profile ( Free Report ) BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. Featured Articles Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter .
.
